https://www.statnews.com/2025/08/04/replimune-skin-cancer-drug-rejection-pazdur-prasad/
0
0
8/4/25 at 8:33am
Organization
STAT
Author
Adam Feuerstein
44 words
0
Comments
The FDA's top regulator of cancer drugs played a key role in the rejection of a skin cancer therapy from Replimune Group, STAT has learned.
You are the first to view
Create an account
or login to join the discussion